Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with Nirogacestat (PF-03084014, gamma-secretase inhibitor) in BCMA-Expressing Cancer Cell Lines

Poster No. 4401

Stephen Eastman^{1*}, Christina Blackwell^{1*}, Julie Krueger^{1*}, Paul M Bojczuk^{1*}, Christopher Shelton^{1*}, James Smothers^{1*}, Ira Gupta^{2*}, and Axel Hoos^{2*}

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by clonal proliferation of plasma cells within the bone marrow. Bcell maturation antigen (BCMA) is a cell-surface receptor required for the survival of plasma cells and is also ubiquitously expressed on MM cells. Belantamab mafodotin (GSK2857916) is a humanized monoclonal anti-BCMA antibody, which is afucosylated and conjugated to the microtubule-disrupting agent monomethyl auristatin-F (MMAF). Upon binding to BCMA on the cell surface, belantamab mafodotin is rapidly internalized and the cytotoxic moiety (cys-mcMMAF) is released, leading to direct cell death.

BCMA is directly shed from the plasma membrane by gammasecretase, a type-I sheddase. In order to further enhance belantamab mafodotin activity, we sought to increase cell surface levels of BCMA by blocking shedding of BCMA with a gammasecretase inhibitor (GSI). We then determined the effect on the activity of belantamab mafodotin by combining Belantamab mafodotin with nirogacestat (PF-03084014), a highly-selective GSI. In order to understand combination effects against immunoconjugate activity, a 3-day proliferation assay on a panel of multiple myeloma and lymphoma cell lines with varying levels of BCMA expression was conducted. The assay showed a 50 to 3,000-fold EC50 shift in cell lines sensitive to belantamab mafodotin across multiple lymphoma cell types.


Antibody-dependent cellular cytotoxicity (ADCC) activity of Belantamab mafodotin in combination with nirogacestat was also examined. In a 24-hour ADCC Jurkat reporter assay, an EC50 shift across multiple BCMA-expressing cell lines was observed. Even cell lines with very low BCMA expression, such as Raji, showed a synergistic increase in ADCC activity in combination with nirogacestat. Cell lines that were non-responsive in the cell proliferation assay, showed activity in the ADCC assay, indicating low-expressing BCMA cell lines remain sensitive to belantamab mafodotin, alone and in combination with nirogacestat.

Synergistic effect from this preclinical work provided rationale to evaluation of belantamab mafodotin in support clinical combination with Nirogacestat in a planned clinical trial (DREAMM-5).


An audio recording accompanies this poster - this is available via the QR code




Results



References 1. Laurent SA, et al. Nat. Comm. 2015; Volume:6-7333.





ADCC activity was measured using Promega's Jurkat ADCC assay. The 24hour assay was conducted using fixed doses of nirogacestat with serial dilutions of belantamab mafodotin. Combination results show a dosedependent increase in ADCC activity.

Disclosures

- Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.
- SE, CS, IG, JK, CB, PB, JS, and AH are employees of GSK and share/stockholders in GSK



¹Immuno-oncology and Combinations, GlaxoSmithKline, Upper Providence, PA, USA; ²RD Oncology, GlaxoSmithKline, Upper Providence, PA, USA

		GSK2857916	Р	
			2.5 uM	.25u
	1A2	10.000	0.0955	0.00
	SK007	0.124	0.0008	0.00
	JJN3	0.002	0.0002	0.00
L0000 L	L363	0.602	0.0010	0.00
	BC3	10.000	0.0015	0.00
	CA46	10.000	0.0219	0.00
	BDCM	0.040	0.0553	0.00
100-	LP1	10.000	0.0048	0.00
	HS445	10.000	0.0005	0.00
	HSSULTAN	10.000	0.0135	0.01
	GA10	0.078	0.0041	0.01
	EB2	0.051	0.0066	0.01
	JVM3	0.562	0.0124	0.01
0.1	NAMALWA	0.100	0.2660	0.01
Qe, ~,~,~,< , ~, ~, ~, ~, ~, ~, ~, ~, ~, ~, ~, ~, ~	CESS	0.376	0.0455	0.01
all in the state with the second of the second in the second second second second second second second second s	HUNS1	1.234	0.0336	0.02
ACA, TON, I'LE TON THE REAL PROPERTY OF THE REAL PROPERTY IN THE REAL PROPERTY OF THE REAL PROPERTY OF THE REAL	ST486	0.981	0.0371	0.02
	ARH77	1.336	0.0200	0.02
CELL LINES	DOHH2	0.123	0.0148	0.03
	RPMI8226	10.000	0.0390	0.03
	EB3	0.280	0.0552	1.53



- Treatment of BCMA-expressing cancer cell lines with Nirogacestat shows increased levels of BCMA cell surface expression and corresponding decreased levels of soluble BCMA
- Combination therapy of belantamab mafodotin with nirogacestat results in synergistic immuno-conjugate activity. We have identified up to 3,000-fold increase in sensitivity to Belantamab mafodotin.
- In a 24-hour assay assay to measure ADCC activity, we showed increased sensitivity to belantamab mafodotin when in combination with nirogacestat.
- Cell lines sensitive to belantamab mafodotin as a single agent showed increased immuno-conjugate and ADCC activity, regardless of lymphoma type.
- A clinical trial evaluating belantamab mafodotin with nirogacestat will be examined in DREAMM-5 platform trial (Study 208887; NCT04126200).

Please find the online version of this poster by scanning the QR (Quick Response) code o via http://tago.ca/ASH1 Copies of this poster obtained through QR and/or text key codes are for personal use only and may not be reproduced without writter permission of the authors.

